Procella Therapeutics
SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014 and built on renowned science from Karolinska Institutet in Sweden, the company combines novel delivery platforms like the Extroducer® with state-of-the-art development and manufacturing of cell therapies. It operates in two segments: Targeted Delivery and Regenerative Medicines, aiming to bridge the gap from scientific discovery to clinical application and address critical diseases such as heart failure, osteoarthritis, and Parkinson’s disease.
Industries
Nr. of Employees
small (1-50)
Procella Therapeutics
Alfred Nobels Allé 150, 146 48 Tullinge, Sweden
Patents
Genetic markers for engraftment of human cardiac ventricular progenitor cells
US-11725244-B2
View DetailsUse of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells
US-11186820-B2
View DetailsGenetic markers for engraftment of human cardiac ventricular progenitor cells
US-10612094-B2
View DetailsUse of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US-10596200-B2
View DetailsUse of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US-10597637-B2
View Details
Genetic markers for engraftment of human cardiac ventricular progenitor cells
US-11725244-B2
View DetailsUse of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells
US-11186820-B2
View DetailsGenetic markers for engraftment of human cardiac ventricular progenitor cells
US-10612094-B2
View DetailsUse of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US-10596200-B2
View DetailsUse of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells
US-10597637-B2
View DetailsProducts
Endovascular direct-to-tissue delivery platform (catheter)
A catheter-based micro‑infusion system designed to access hard‑to‑reach tissues via the endovascular route and deliver therapeutic payloads directly through the vessel wall; covered by granted patents and cleared by the US FDA for abdominal organ use.
Cardiac progenitor cell therapy program (clinical-stage development)
A pluripotent stem cell–derived cardiac progenitor cell program with preclinical evidence of engraftment, myocardial regeneration and functional improvement; progressed through GLP toxicology and supported by GMP manufacturing for planned Phase I studies.
Pluripotent stem cell–derived dopaminergic neuron program (Parkinson’s disease)
A pluripotent stem cell–based technology to generate transplantation-ready dopaminergic neurons with improved yield and reduced off‑target cells; acquired development rights via collaboration to advance toward clinical development.
Endovascular direct-to-tissue delivery platform (catheter)
A catheter-based micro‑infusion system designed to access hard‑to‑reach tissues via the endovascular route and deliver therapeutic payloads directly through the vessel wall; covered by granted patents and cleared by the US FDA for abdominal organ use.
Cardiac progenitor cell therapy program (clinical-stage development)
A pluripotent stem cell–derived cardiac progenitor cell program with preclinical evidence of engraftment, myocardial regeneration and functional improvement; progressed through GLP toxicology and supported by GMP manufacturing for planned Phase I studies.
Pluripotent stem cell–derived dopaminergic neuron program (Parkinson’s disease)
A pluripotent stem cell–based technology to generate transplantation-ready dopaminergic neurons with improved yield and reduced off‑target cells; acquired development rights via collaboration to advance toward clinical development.
Services
cGMP clinical manufacturing of sterile biological medicinal products and in-house QC/release testing for clinical and preclinical stages; available for internal programs and third-party manufacturing.
Out‑licensing of a catheter-based direct-to-tissue delivery platform to external companies and execution of strategic collaboration agreements.
Partnerships to co-develop stem cell and mRNA-based therapies from preclinical proof-of-concept through clinical translation, including process development and technology transfer.
Manufacture and supply of clinical-grade cell products for Phase I and early-phase trials, including scaling production volumes and supporting regulatory documentation for trials.
cGMP clinical manufacturing of sterile biological medicinal products and in-house QC/release testing for clinical and preclinical stages; available for internal programs and third-party manufacturing.
Out‑licensing of a catheter-based direct-to-tissue delivery platform to external companies and execution of strategic collaboration agreements.
Partnerships to co-develop stem cell and mRNA-based therapies from preclinical proof-of-concept through clinical translation, including process development and technology transfer.
Manufacture and supply of clinical-grade cell products for Phase I and early-phase trials, including scaling production volumes and supporting regulatory documentation for trials.
Expertise Areas
- Endovascular targeted delivery
- Cell therapy development (pluripotent stem cell–derived products)
- GMP manufacturing and quality control for ATMPs
- Cell-mediated mRNA delivery and localized protein expression
Key Technologies
- Endovascular micro-catheter direct-to-tissue delivery
- Cell-mediated mRNA delivery
- Pluripotent stem cell–derived cardiac progenitors
- Pluripotent stem cell–derived dopaminergic neuron preparations
News & Updates
Procella has completed manufacturing of cells for GLP Tox, a prerequisite for Phase I clinical studies in humans, which will begin in 2024. The company is proud to be a supplier to AstraZeneca for these trials.
The development of the patented Extroducer device continues, with plans to conduct first human trials soon. The device allows direct delivery of therapies into organs or tumors, opening new treatment possibilities.
Development of a cell-mediated delivery platform has shown promising results, especially for protecting mRNA therapies from immune attack, enabling higher and longer-lasting protein production.
The FDA has approved the Extroducer catheter for approach to the US market, enabling its use in organs such as the kidney, pancreas, and liver.
Procella has received updated approval from the Swedish Medicinal Product Agency for manufacturing and quality control of cell therapy products, supporting clinical development.
A new European patent has been granted for the Extroducer delivery platform, covering the design of its distal part, providing protection in 39 countries.
Procella has completed manufacturing of cells for GLP Tox, a prerequisite for Phase I clinical studies in humans, which will begin in 2024. The company is proud to be a supplier to AstraZeneca for these trials.
The development of the patented Extroducer device continues, with plans to conduct first human trials soon. The device allows direct delivery of therapies into organs or tumors, opening new treatment possibilities.
Development of a cell-mediated delivery platform has shown promising results, especially for protecting mRNA therapies from immune attack, enabling higher and longer-lasting protein production.
The FDA has approved the Extroducer catheter for approach to the US market, enabling its use in organs such as the kidney, pancreas, and liver.
Procella has received updated approval from the Swedish Medicinal Product Agency for manufacturing and quality control of cell therapy products, supporting clinical development.
A new European patent has been granted for the Extroducer delivery platform, covering the design of its distal part, providing protection in 39 countries.